Edgar Filing: GAMMACAN INTERNATIONAL INC

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-QSB

(Mark One)

x	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2008

o	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _________ to _________

Commission file number: 0-32835

GAMMACAN INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

33-0956433
(IRS Employer Identification
No.)

Kiryat Ono Mall

Azorim Center A

39 Jerusalem St.,

55423 Kiryat Ono, Israel

(Address of principal executive offices)

+ 972 3 7382616

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

APPLICABLE ONLY TO CORPORATE ISSUERS:

State the number of shares outstanding of each of the registrant’s classes of common equity, as of the latest practicable date: 44,958,917 shares issued and outstanding as of August 1, 2008.

GAMMACAN INTERNATIONAL, INC.

FORM 10-QSB

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION		1
ITEM 1 - FINANCIAL STATEMENTS		1
ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF PLAN OF OPERATION		13
ITEM 3A(T) - CONTROLS AND PROCEDURES		20
PART II – OTHER INFORMATION		22
ITEM 1 - LEGAL PROCEEDINGS		22
ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS		22
ITEM 3 - DEFAULTS UPON SENIOR SECURITIES		22
ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS		22
ITEM 5 - OTHER INFORMATION		22
ITEM 6 - EXHIBITS		23

PART I

ITEM 1 - FINANCIAL STATEMENTS

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

INTERIM FINANCIAL STATEMENTS

AS OF JUNE 30, 2008

TABLE OF CONTENTS

		Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) :
Balance Sheets as of June 30, 2008 and September 30, 2007		2
Statements of Operations - Three and Nine months ended June 30, 2008 and 2007 and the Period from Inception (October 6, 1998) through June 30, 2008		3
Statements of Changes in Stockholders’ Equity - Period from Inception (October 6, 1998) through June 30, 2008		4
Statements of Cash Flows - Nine Months ended June 30, 2008 and 2007 and the Period from Inception (October 6, 1998) through June 30, 2008		5
Notes to Financial Statements		6-12

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEETS

(US $, except share data)

	June 30, 2008			September 30, 2007

	(Unaudited)			(Audited)

Assets
CURRENT ASSETS:
Cash and cash equivalents	$	861,531		$	4,048,583
Prepaid expenses		16,601			9,851
Other		49,243			47,271

Total current assets		927,375			4,105,705

FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT		—			49,281

LONG TERM DEPOSITS		1,873			18,590

PROPERTY AND EQUIPMENT, NET		35,447			26,338

Total assets	$	964,695		$	4,199,914

Liabilities and stockholders’ equity
CURRENT LIABILITIES:
Accounts payable	$	393,478		$	797,515
Payroll and related accruals		121,657			130,223

Total current liabilities		515,135			927,738

COMMITMENTS (NOTE 2)
LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT		21,296			71,338

STOCKHOLDERS’ EQUITY:
Preferred stock, $ 0.0001 par value (20,000,000 shares authorized; none issued and outstanding)
Common stock, $ 0.0001 par value (200,000,000 authorized shares; 44,958,917 and 44,958,917 shares issued and outstanding as of June 30, 2008 and September 30, 2007, respectively)		4,495			4,495
Additional paid-in capital		9,486,016			8,968,930
Warrants		3,203,600			3,203,600
Deficit accumulated during the development stage		(12,265,847	)		(8,956,187	)
Services not yet rendered		—			(20,000	)

Total stockholders’ equity		428,264			3,200,838

Total liabilities and stockholders’ equity	$	964,695		$	4,199,914

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(US $, except share data)

	Nine months ended June 30						Three months ended June 30						Period from October 6, 1998* through June 30,

	2008			2007			2008			2007			2008

	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)

RESEARCH AND DEVELOPMENT COSTS	$	1,350,956		$	762,778		$	450,279		$	279,908		$	4,064,134
GENERAL AND ADMINISTRATIVE EXPENSES		1,979,379			2,902,678			591,960			1,270,878			8,358,253

OPERATING LOSS		3,330,335			3,665,456			1,042,239			1,550,786			12,422,387
FINANCIAL INCOME		(62,446	)		(97,462	)		(6,456	)		(65,323	)		(279,367	)
FINANCIAL EXPENSES		41,771			33,135			4,597			11,667			105,202

LOSS BEFORE TAXES ON INCOME		3,309,660			3,601,129			1,040,380			1,497,130			12,248,222
TAXES ON INCOME		—			37,013			—			20,157			30,000

LOSS FROM OPERATIONS OF THE COMPANY AND ITS CONSOLIDATED SUBSIDIARY		3,309,660			3,638,142			1,040,380			1,517,287			12,278,222
MINORITY INTERESTS IN LOSSES OF SUBSIDIARY		—			—			—			—			(12,375	)

NET LOSS FOR THE PERIOD	$	(3,309,660	)	$	(3,638,142	)	$	(1,040,380	)	$	(1,517,287	)	$	(12,265,847	)

BASIC AND DILUTED LOSS PER COMMON SHARE	$	(0.07	)	$	(0.10	)	$	(0.02	)	$	(0.03	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON SHARE		44,958,917			35,744,894			44,958,917			44,846,265

* Inception date, see note 1a.

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(US $, except share data)

	Number of Shares		Common Stock Amount			Additional paid-in capital			Warrants		Deficit accumulated during the development stage			Services not yet rendered		Total

Changes during the period from October 6, 1998 (date of inception) to September 30, 2005 (audited):
Common stock and warrants issued for cash	57,506,498		$	5,750		$	782,141		$	139,494		—		—		$	927,385
Contributed capital							7,025										7,025
Cancellation of shares at June 8, 2004	(32,284,988	)		(3,228	)		3,228
Gain on issuance of subsidiary Stock to third party							86,625										86,625
Common stock and warrants issued for cash on November 11, 2004, net of issuance costs	978,000			97			766,630			367,892							1,134,619
Common stock and warrants issued for cash on January 25, 2005, net of issuance costs	32,000			3			24,760			12,037							36,800
Issuance of warrants to Consultants							97,192										97,192
Net loss												(1,712,618	)				(1,712,618	)

Balance at September 30, 2005 (audited)	26,231,510			2,622			1,767,601			519,423		(1,712,618	)	—			577,028
Common stock and warrants issued for cash on October 31, 2005, net of issuance costs	666,666			67			365,670			72,410							438,147
Common stock and warrants issued for cash on December 20, 2005, net of issuance costs	1,555,556			156			804,998			269,641							1,074,795
Options issued to employees and directors							163,517										163,517
Options and warrants issued to non-employees							70,498										70,498
Net loss												(2,064,795	)				(2,064,795	)

Balance at September 30, 2006 (audited)	28,453,732			2,845			3,172,284			861,474		(3,777,413	)	—			259,190
Common stock and warrants issued for cash on February 27, 2007, net of issuance costs	16,250,000			1,625			3,652,640			2,231,459							5,885,724
Common stock issued as part of the prepayment of the convertible promissory note	33,753			3			13,498										13,501
Amendment of warrants exercise price							(110,667	)		110,667							—
Stock based compensation expenses:
Common stock issued for services	221,432			22			149,978										150,000
Services not yet rendered														(20,000	)		(20,000	)
Options issued to employees and directors							1,713,169										1,713,169
Options and warrants issued to non-employees							378,028										378,028
Net loss												(5,178,774	)				(5,178,774	)

Balance at September 30, 2007 (audited)	44,958,917			4,495			8,968,930			3,203,600		(8,956,187	)	(20,000	)		3,200,838
Full accretion in respect of services not yet rendered														20,000			20,000
Options issued to employees and directors							458,099										458,099
Options and warrants issued to non-employees							58,987										58,987
Net loss												(3,309,660	)				(3,309,660	)

Balance at June 30, 2008 (unaudited)	44,958,917		$	4,495		$	9,486,016		$	3,203,600	$	(12,265,847	)	—		$	428,264

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(US dollars)

	Nine months ended June 30,						Period from October 6, *1998 to June 30,**

	2008			2007			2008

	Unaudited			Unaudited			Unaudited

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$	(3,309,660	)	$	(3,638,142	)	$	(12,265,847	)
Adjustments required to reconcile net loss to net cash used in operating activities:
Income and expenses not involving cash flows:
Depreciation		10,496			6,225			25,699
Exchange differences on long term deposits		588			—			850
Common stock issued for services		20,000			106,001			166,501
Minority interests in losses of a subsidiary		—			—			(12,375	)
Write off of in process research and development		—			—			100,000
Employees and consultants stock based compensation expenses		517,086			1,523,709			2,902,432
Increase (Decrease) in liability for employee rights upon retirement		(761	)		24,066			70,577
Changes in operating assets and liabilities:
Increase in prepaid expenses		(6,750	)		(32,825	)		(16,601	)
Decrease (Increase) in other current assets		14,157			(8,749	)		(32,454	)
Increase (Decrease) in current liabilities		(412,603	)		378,032			515,135

Net cash used in operating activities		(3,167,447	)		(1,641,683	)		(8,546,083	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in long term deposits		—			(1,504	)		(20,512	)
Funds in respect of employee rights upon retirement		—			(19,111	)		(49,281	)
Purchase of property and equipment		(19,605	)		(5,304	)		(61,146	)

Net cash used in investing activities		(19,605	)		(25,919	)		(130,939	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock and warrants net of issuance costs		—			5,885,724			9,538,553

Net cash provided by financing activities		—			5,885,724			9,538,553

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(3,187,052	)		4,218,122			861,531
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		4,048,583			538,738			—

BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	861,531		$	4,756,860		$	861,531

Supplementary information on investing activity not involving cash flow:

During the second quarter approximately $50,000 funded in respect of employee rights upon retirement, was released from the insurance company directly to the employees.

* Inception date, see note 1a.

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - GENERAL:

Operation:

GammaCan International, Inc. (a Development Stage Company) was incorporated on October 6, 1998, under the laws of the State of Delaware, under the name of San Jose International, Inc. Unless the context indicates otherwise, references to the “Company” refer to GammaCan International, Inc. and its Israeli subsidiary, GammaCan Ltd (the “Subsidiary”).

The Company is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with Statement of Financial Accounting Standard (“SFAS”) No. 7 “Accounting and Reporting by Development Stage Enterprises”.

The Company’s lead product candidate, VitiGam™, is an anti-cancer immunotherapy derived entirely from the plasma of donors with vitiligo, a benign skin condition affecting up to 2% of the general population. The Company is developing VitiGam™ to treat melanoma. The Company has demonstrated that plasma from individuals with vitiligo contains anti-melanoma activities, and the Company is seeking to develop VitiGam™ for the treatment of Stage III and Stage IV melanoma.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has net losses for the period from inception (October 6, 1998) through June 30, 2008 of $12,265,847, as well as negative cash flow from operating activities. Based upon the Company’s existing spending commitments, the Company may not have sufficient cash resources to meet its liquidity requirements through September 30, 2008. Accordingly, these factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is engaged in ongoing financing discussions with third party investors and existing shareholders to raise the necessary funds for future research and development activities and general and administrative expenses in the public and private equity markets. Although there is no assurance that we will be successful with these initiatives, management expects to secure the necessary financing as a result of the above ongoing discussions.

These financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability.

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - GENERAL (continued):

Unaudited interim financial information

The accompanying unaudited financial statements of the Company and the Subsidiary have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-QSB and Item 310 of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. For further information, refer to the financial statements and footnotes thereto included in the consolidated annual report on Form 10-KSB for the year ended September 30, 2007.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine-month period ended June 30, 2008, are not necessarily indicative of the results that may be expected for the year ended September 30, 2008.

Income tax

In June 2006, the FASB issued Interpretation No. 48, “Accounting for Uncertainty in Income Taxes” (“FIN 48”). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes” (“FAS 109”). This interpretation prescribes a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. FIN 48 also provides guidance on derecognition of tax positions, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure, and transition. The Company adopted FIN 48 effective October 1, 2007. FIN 48 requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company had no unrecognized tax benefits as of October 1, 2007. The result of the implementation of FIN 48 did not have any impact on the Company’s financial statements. The Company recognizes interest and penalties related to its tax contingencies as income tax expense. As of October 1, 2007, the Company recorded $30,000 of penalties related to tax contingencies.

As of October 1, 2007, the Company is subject to Israeli income tax examinations and to U.S. Federal income tax examinations for the tax years of 2004 through 2007. As of June 30, 2008, the Company did not record any change to its unrecognized tax benefits.

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - GENERAL (continued):

Recently issued accounting pronouncements

In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157, “Fair Value Measurements” (“SFAS 157”). SFAS 157 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years (October 1, 2008, for the Company). The FASB has also issued FSP No. FAS 157-2, “Effective Date of FASB Statement No. 157”, which defers implementation of SFAS 157 as it relates to non-financial assets and non-financial liabilities that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis. The Company is currently assessing the impact that SFAS 157 may have on its results of operations and financial position.

In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities - Including an amendment of FASB Statement No. 115” (“SFAS 159”). SFAS 159 is expected to expand the use of fair value accounting but does not affect existing standards which require certain assets or liabilities to be carried at fair value. The objective of SFAS 159 is to improve financial reporting by providing companies with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. Under SFAS 159, a company may choose, at its initial application or at other specified election dates, to measure eligible items at fair value and report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date. SFAS 159 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years (October 1, 2008, for the Company). If a company elects the fair value option for its existing assets and liabilities, the effect as of the adoption date, shall be reported as a cumulative-effect adjustment to the opening balance of retained earnings. The Company is currently assessing the impact that SFAS 159 may have on its financial position.

In December 2007, the FASB issued Statement of Financial Accounting Standards No. 141 (revised 2007), “Business Combinations” (“SFAS 141(R)”). SFAS 141(R) changes the accounting for business combinations, including the measurement of acquirer shares issued in consideration for a business combination, the recognition of contingent consideration, the accounting for contingencies, the recognition of capitalized in-process research and development, the accounting for acquisition-related restructuring cost accruals, the treatment of acquisition related transaction costs and the recognition of changes in the acquirer’s income tax valuation allowance and income tax uncertainties. SFAS 141(R) applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. Early application is prohibited. The Company will be required to adopt SFAS 141(R) on October 1, 2009.

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - GENERAL (continued):

In December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements, an Amendment of ARB No. 51” (“SFAS 160”). SFAS 160 amends ARB 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. An ownership interest in subsidiaries held by parties other than the parent should be presented in the consolidated statement of financial position within equity, but separate from the parent’s equity. SFAS 160 requires that changes in a parent’s ownership interest while the parent retains its controlling financial interest in its subsidiary should be accounted for similarly as equity transactions. When a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary should be initially measured at fair value, with any gain or loss recognized in earnings. SFAS 160 requires consolidated net income to be reported at amounts that include the amounts attributable to both the parent and the noncontrolling interest. It also requires disclosure, on the face of the consolidated income statement, of the amounts of consolidated net income attributable to the parent and to the noncontrolling interests. SFAS 160 is effective for fiscal years (including interim periods within those fiscal years) beginning on or after December 15, 2008 (October 1, 2009 for the Company). Earlier adoption is prohibited. The statement shall be applied prospectively as of the beginning of the fiscal year in which it is initially applied, except for the presentation and disclosure requirement which shall be applied retrospectively for all periods presented. The Company is currently evaluating the impact SFAS 160 will have on its consolidated financial statements.

In June 2007, the Emerging Issues Task Force (EITF) issued Issue No. 07-03, “Accounting for Nonrefundable Advance Payments for Goods or Services Received to Be Used in Future Research and Development Activities” (“EITF No. 07-03”). EITF No. 07-03 requires that nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities be deferred and amortized over the period that the goods are delivered or the related services are performed, subject to an assessment of recoverability. The provisions of EITF 07-03 will be effective for financial statements issued for fiscal years beginning after December 15, 2007, and interim periods within those fiscal years (October 1, 2008, for the Company). The provisions of EITF No. 07-03 are applicable for new contracts entered into on or after the effective date. Earlier application is not permitted. The Company is currently evaluating the impact EITF 07-03 will have on its consolidated financial statements.

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - GENERAL (continued):

In December 2007, the FASB ratified EITF Issue No. 07-01, “Accounting for Collaborative Arrangements” (“EITF 07-01”). EITF 07-01 defines collaborative arrangements and establishes reporting requirements for transactions between participants in a collaborative arrangement and between participants in the arrangement and third parties. EITF 07-01 also establishes the appropriate income statement presentation and classification for joint operating activities and payments between participants, as well as the sufficiency of the disclosures related to these arrangements. EITF 07-01 is effective for fiscal years beginning after December 15, 2008 (October 1, 2009, for the Company). EITF 07-01 shall be applied using modified version of retrospective transition for those arrangements in place at the effective date. An entity should report the effects of applying this Issue as a change in accounting principle through retrospective application to all prior periods presented for all arrangements existing as of the effective date, unless it is impracticable to apply the effects of the change retrospectively. The Company is currently assessing the impact that EITF 07-01 may have on its results of operations and financial position.

In March 2008, the FASB issued SFAS Statement No. 161 “Disclosures about Derivative Instruments and Hedging Activities” (“SFAS No. 161”). The new standard is intended to improve financial reporting about derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entity’s financial position, financial performance, and cash flows. It is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged (October 1, 2009, for the Company). The new standard also improves transparency about the location and amounts of derivative instruments in an entity’s financial statements; how derivative instruments and related hedged items are accounted for under SFAS No. 133 “Accounting for Derivative Instruments and Hedging Activities” (“SFAS No. 133”); and how derivative instruments and related hedged items affect its financial position, financial performance, and cash flows. The Company is currently evaluating the effect SFAS No. 161 will have on its financial statement presentations.

In May 2008, the FASB issued SFAS No. 162, “The Hierarchy of Generally Accepted Accounting Principles”. The statement is intended to improve financial reporting by identifying a consistent hierarchy for selecting accounting principles to be used in preparing financial statements that are presented in conformity with U.S. generally accepted accounting principles (GAAP). SFAS 162 is effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board Auditing amendments to AU Section 411, “The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles”. The Company does not expect the adoption of SFAS 162 to have a material impact on its results of operations, financial position or cash flows.

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 2 - COMMITMENTS:

On December 13, 2007, the Company entered into a Share Purchase Agreement effective as of November 26, 2007 with ARP Biomed, Ltd. (“ARP”). The Share Purchase Agreement provided that subject to fulfillment of certain closing conditions, including the receipt of an Israeli tax ruling, ARP will sell to the Company 12.5% of the issued and outstanding shares of the Subsidiary such that at closing the Company will own 100% of the issued and outstanding shares of the Subsidiary. In consideration for such sale, the Company originally agreed to issue to ARP, at closing, 2,697,535 shares of its common stock, valued at $1,348,768, calculated based upon the average of the closing price for the period which is two days before and after November 26, 2007, a warrant to acquire 1,123,973 shares of its common stock and an additional warrant to acquire 449,589 shares of its common stock. The Share Purchase Agreement was subsequently amended on August 11, 2008. (See Note 5).

On May 30, 2008, the Subsidiary entered into a Contract Manufacture Agreement (“Contract Manufacture Agreement”) with Bio Products Laboratory (“BPL”). Under the terms of the Contract Manufacture Agreement, the Subsidiary is engaging BPL as its manufacturer of VitiGam™ from plasma derived from Vitiligo donors. The Contract Manufacture Agreement further provides that BPL will manufacture VitiGam™ utilizing its proprietary GAMMAPLEX process and will supply the Subsidiary with VitiGam™ for its immediate clinical testing needs and for future commercial sale. In addition, the agreement provides that BPL will make available to the Subsidiary technical, scientific and other data, including specific support for its U.S. regulatory filings and future regulatory approvals in other markets. Under the terms of the agreement, the Subsidiary has agreed to pay to BPL certain manufacturing and service fees as well as royalties for the manufacture of VitiGam™.

NOTE 3 - STOCK BASED COMPENSATION:

The following is a transaction that took place during the quarter ended June 30, 2008:

On April 10, 2008, options to purchase 50,000 shares of the Company’s common stock were granted under the Company’s 2007 Global Share Option Plan to an employee. The options are exercisable at $0.37 per share (equivalent to the traded market price on the date of grant) with one third vesting on each of the first, second and third anniversary of the date of grant. The fair value of these options on the date of grant was $12,332, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 82%; risk-free interest rates of 2.66%; and expected lives of 5.02 years.

NOTE 4 - LOSS PER SHARE:

The total number of common stock options and warrants excluded from the calculations of diluted net loss was 25,022,558 for the nine months ended June 30, 2008 (25,062,558 for the nine months ended June 30, 2007).

GAMMACAN INTERNATIONAL, INC.

(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 5 – SUBSEQUENT EVENTS:

On August 11, 2008, the Company entered into an Amendment Agreement with ARP Biomed, Ltd. (“ARP”) made as of June, 2008 (the “Amendment Agreement”) amending, among other things the Share Purchase Agreement dated November 26, 2007 between the Company and ARP. The Share Purchase Agreement provided that subject to fulfillment of certain closing conditions, including the receipt of an Israeli tax ruling, ARP will sell to the Company 12.5% of the issued and outstanding shares of the Subsidiary such that at closing the Company will own 100% of the issued and outstanding shares of the Subsidiary. In consideration for such sale, the Company originally agreed to issue to ARP, at closing, 2,697,535 shares of its common stock, a warrant to acquire 1,123,973 shares of its common stock and an additional warrant to acquire 449,589 shares of its common stock. According to the Amendment Agreement, the number of shares of common stock issuable to ARP at closing and upon receipt of an Israeli tax ruling has been increased to 3,389,902 shares of common stock and no warrants will be issued. Subsequently, on August 13, 2008, the Company conducted a closing of the Share Purchase Agreement as amended by the Amendment Agreement. The acquisition is to be accounted for by the purchase method. The purchase price will be allocated to in-process research and development.

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF PLAN OF OPERATION

The following information should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this Quarterly Report.

We have included in this Quarterly Report certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 concerning our business, operations and financial condition. “Forward-looking statements” consist of all non-historical information, and the analysis of historical information, including the references in this Quarterly Report to future revenues, collaborative agreements, future expense growth, future credit exposure, earnings before interest, taxes, depreciation and amortization, future profitability, anticipated cash resources, anticipated capital expenditures, capital requirements, and our plans for future periods. In addition, the words “could”, “expects”, “anticipates”, “objective”, “plan”, “may affect”, “may depend”, “believes”, “estimates”, “projects” and similar words and phrases are also intended to identify such forward-looking statements.

Actual results could differ materially from those projected in our forward-looking statements due to numerous known and unknown risks and uncertainties, including, among other things, unanticipated technological difficulties, the length, scope and outcome of our clinical trial, costs related to intellectual property, cost of manufacturing and higher consulting costs, product demand, changes in domestic and foreign economic, market and regulatory conditions, the inherent uncertainty of financial estimates and projections, the uncertainties involved in certain legal proceedings, instabilities arising from terrorist actions and responses thereto, and other considerations described as “Risk Factors” in our other filings with the SEC. Such factors may also cause substantial volatility in the market price of our common stock. All such forward-looking statements are current only as of the date on which such statements were made. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

As used in this Quarterly Report, the terms “we”, “us”, “our”, “Company” and “GammaCan” mean GammaCan International, Inc. and our subsidiary, GammaCan, Ltd., unless otherwise indicated.

All dollar amounts refer to US dollars unless otherwise indicated.

Overview

We are a development stage company and currently have no revenue from operations. Other than existing cash reserves and our intellectual property we have no significant assets, tangible or intangible. Presently, we do not have sufficient cash resources to meet our liquidity requirements through September 30, 2008 and we expect to seek to raise additional funds during that time period. There can be no assurance that we will raise additional funds on a timely basis, on terms acceptable to us or at all and there can be no assurance that we will generate revenues in the future, or that we will be able to operate profitably in the future, if at all. We have incurred net losses in each fiscal year since inception of our operations.

Plan of Operation

Short Term Business Strategy

We are a life science company focused on the development of immunotherapy and related approaches to treat cancer. We are focused on the use of intravenous immunoglobulins, or IgGs, derived from human plasma to treat melanoma, prostate, and colon cancers. We believe that IgG therapy may be the basis of a more effective and efficient cancer treatment both as mono and as combination therapy as well as an adjuvant for cancer treatments (IgGs used in concert with other proprietary pharmaceuticals). Our business objective is to become a recognized leader in the development of immunotherapy, including IgG-based therapies and related approaches to treat cancer.

IgG-based immunotherapy will require regulatory approval before being commercially marketed for human therapeutic use. Clinical trials generally include three phases that, together, may take several years to complete. Phase I clinical studies are conducted primarily to establish safety and determine the maximum tolerated dose, or MTD. Phase II studies are designed to determine preliminary efficacy and establish dosing. Phase III studies are conducted to demonstrate therapeutic efficacy in a statistically significant number of patients, at an optimal dose level, method or route of delivery into the body, and a schedule of administration. Once clinical trials are successfully completed, products may receive regulatory approval.

We are pursuing the development of IgG-based technology to develop therapies for the treatment of melanoma, as well as therapies directed toward disrupting the blood supply to cancers, referred to as anti-angiogenesis.

Melanoma: Our lead product candidate, VitiGam™, is a first-in-class anti-cancer immunotherapy derived entirely from the plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to two percent of the general population. We have demonstrated that plasma from individuals with vitiligo contains anti-melanoma activities. Based on this, we are developing VitiGam™ to initially address Stage III and Stage IV melanoma and possibly earlier stages of melanoma at a future time.

In June 2007, we completed a non-FDA Phase II clinical trial designed to test the safety and efficacy of “standard” IgG (collected and manufactured from general population donors, which may have included donors with vitiligo) in patients with prostate cancer, colon cancer and melanoma. In this trial, no serious untoward effects of IgGs were noted. In one patient with melanoma, the cancer remained stable or improved over eight cycles of therapy (approximately ten months).

In addition to the pre-clinical evidence we have accumulated using vitiligo-derived plasma, the above observations provide further validation for our plan to develop VitiGam™.

We plan to file an Investigational New Drug Application, or IND, for VitiGam™ in the near future. We believe that the FDA is well acquainted with IgG-based therapies and their safety profiles resulting from a long history of regulatory approvals of IgG-based products.

In addition to VitiGam™, we are also developing the following:

•

Next generation (recombinant) VitiGam™ - VitiGam™ is currently manufactured as a mixture that largely consists of IgG molecules (antibodies of the IgG

type). We anticipate that within this mixture, only a subset of IgG molecules will be responsible for the biological activity of VitiGam™. “Next generation” VitiGam™ will be composed of only the IgGs required to exert the anti-melanoma effect, thereby creating a more effective compound. Identifying the relevant IgGs may also permit cost reductions; and

•

Cancer vaccines based on VitiGam™ - An “off-the-shelf” cancer vaccine is considered a “silver bullet” in cancer therapy. We anticipate that based on our evolving understanding of the specific IgG molecules responsible for the biological activity of VitiGam™, we may be in a position to identify the corresponding antigens that may be used to develop melanoma cancer vaccines.

Anti-angiogenesis: We are developing additional novel IgG-based therapies for cancer and other diseases. These therapies are based on the disruption of the blood supply to cells. Our scientists have shown that several mechanisms may be involved in mediating the anti-cancer effects of IgG-based immunotherapies. Angiogenesis is one of a number of well known pathways to deprive cells from their blood supply.

In June 2007, we announced the discovery of proprietary IgG sub-fractions in human plasma, which contain potent anti-angiogenic properties. These sub-fractions may be used for treatment of disorders resulting from neovascularization (the formation of new blood vessels or angiogenesis).

We have established a pre-clinical development program to define and characterize these anti-angiogenic anti-cancer fractions and to test their biological activity in animal models. We believe that successfully developed therapies derived from our novel IgG sub-fractions have the potential to address multi-billion dollar markets. For example, Avastin®, also known as bevacizumab, counteracts VEGF, a growth factor which stimulates neovascularization, and is approved to treat colon and other cancers. Sales for Avastin® in 2007 were in excess of $2 billion.

We are also contemplating conducting additional clinical trials to test new formulations and/or combinations of IgG-based immunotherapy candidates and to test these formulations and/or methods for different cancers at different stages of disease progression with varying dosages and routes of administration. To achieve this, we may elect to partner with a pharmaceutical company to conduct these further clinical trials, although there can be no assurance that we will locate a pharmaceutical company able, or willing, to partner with us on terms commercially acceptable to us, in order to attain broad-based regulatory approval.

Although there can be no assurance that the FDA will approve VitiGam™, or any other IgG immunotherapy candidate, we expect that, at a minimum, it will take a number of years to receive final approval and registration for commercial use as an anti-cancer agent. Our strategy is to collaborate with a suitable partner, although there can be no assurance that we will locate a suitable partner, to support late stage (Phase III) clinical development, registration and/or sales for our IgG-based cancer products.

Long Term Business Strategy

If our IgG-based cancer immunotherapy candidates show significant promise in clinical trials, and at this preliminary stage there can be no assurance that any such immunotherapy candidates will show significant promise, we plan to ultimately seek a strategic commercial

partner, or partners, with extensive experience in the development, commercialization, and marketing of cancer drugs and/or other infused therapeutic proteins, although there can be no assurance that we will locate a strategic commercial partner or partners on terms commercially acceptable to us. We anticipate such partner or partners would be responsible for, or substantially support, late stage clinical trials (Phase III) to ensure regulatory approvals and registrations in the appropriate territories in a timely manner. We further anticipate that the partner, or partners, would be responsible for sales and marketing of our IgG-based immunotherapies in certain agreed upon territories. Such planned strategic partnership, or partnerships, may provide a marketing and sales infrastructure for our products as well as financial and operational support for global clinical trials, post marketing studies, label expansions and other regulatory requirements concerning future clinical development in the United States and elsewhere. Any future strategic partner, or partners, may also provide capital and expertise that would enable the partnership to develop new formulations of IgG cancer immunotherapy suitable for patients at different stages of disease progression as well as IgG derivatives. Under certain circumstances, we may determine to develop one or more of our IgG based cancer immunotherapies on our own, either world-wide or in select territories.

Other Planned Research and Development Activities

In addition to conducting early-stage clinical trials, we plan to conduct pre-clinical research to accomplish the following:

•

Further deepen and broaden our understanding of the biology of our IgG products in cancer;

•

Develop alternative delivery systems and determine the optimal dosage for different patient groups;

•

Investigate alternative sources of immunoglobulin other than human plasma (i.e. recombinant);

•

Develop novel IgG-based therapies; and

•

Develop successor products.

Our plan is to patent any successful inventions resulting from our future research activities and to exploit any other means that may exist to protect our future IgG anti-cancer therapies in the commercial markets; although at this early stage there can be no assurance that there will be any successful inventions resulting from such research activities.

Other Planned Strategic Activities

In addition to developing our own IgG-based anti-cancer therapies drug portfolio, we are, on an on-going basis, considering in-licensing and other means of obtaining additional lead molecules of technologies to complement and/or expand our current product portfolio. Our goal is to create a well-balanced product portfolio that includes lead molecules in different stages of development and addresses different medical needs.

Critical accounting policies and estimates

Management’s discussion and analysis of the financial condition and results of operations is based upon the consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates and judgments. We base our estimates on various factors, including historical experience that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other resources. Actual results may differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.

Going concern assumption

The accompanying financial statements have been prepared assuming that we will continue as a going concern. We have net losses for the period from inception (October 6, 1998) through June 30, 2008 of $12,265,847, as well as negative cash flow from operating activities. Based upon our existing spending commitments, we do not have sufficient cash resources to meet our liquidity requirements through September 30, 2008. Accordingly, these factors raise substantial doubt about our ability to continue as a going concern. Management is engaged in ongoing financing discussions with third party investors and existing shareholders to raise the necessary funds for future research and development activities and general and administrative expenses in the public and private equity markets. Although there is no assurance that we will be successful with these initiatives, management expects to secure the necessary financing as a result of the above ongoing discussions.

The financial statements do not include any adjustments that may be necessary should we be unable to continue as a going concern. Our continuation as a going concern is dependent on our ability to obtain additional financing as may be required and ultimately to attain profitability.

Valuation of options and warrants

We granted options to purchase shares of our common stock to employees and consultants and issued warrants in connection with fund raising.

The fair value of each stock option grant was estimated at the date of grant using a Black-Scholes option pricing model. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The expected term is the length of time until the expected dates of exercising the options, based on estimated data regarding employees’ exercise behavior.

We account for equity instruments issued to third party service providers (non-employees) in accordance with the fair value based on an option-pricing model, pursuant to the guidance in EITF 96-18 “Accounting for Equity Instruments That Are Issued to Other Than

Employees for Acquiring, or in Conjunction with Selling Goods or Services”. The fair value of the options granted is revalued over the related service periods and recognized using the accelerated method.

Deferred income taxes

Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. We have provided a full valuation allowance with respect to our deferred tax assets.

Regarding our Israeli subsidiary, GammaCan Ltd, paragraph 9(f) of FAS 109, “Accounting for Income Taxes”, prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the above mentioned differences are not reflected in the computation of deferred tax assets and liabilities.

Income Taxes

The Company adopted FIN 48 effective October 1, 2007. FIN 48 requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company had no unrecognized tax benefits as of October 1, 2007. The result of the implementation of FIN 48 did not have any impact on the Company’s financial statements.

Results of Operations

The following table summarizes certain statements of operations data for the Company for the nine months period ended June 30, 2008 and 2007 (in US$):

	Nine months ended

Operating Data:	June 30, 2008			June 30, 2007

Research and development costs	$	1,350,956		$	762,778
General and administrative expenses		1,979,379			2,902,678
Financial income, net		(20,675	)		(64,327	)

Loss before tax on income		3,309,660			3,601,129
Taxes on Income		—			37,013

Net loss for the period	$	(3,309,660	)	$	(3,638,142	)

Loss per common share – basic and diluted	$	(0.07	)	$	(0.10	)

Weighted average common shares outstanding		44,958,917			35,744,894

Research and development costs

Research and development expenses are the costs incurred in the process of our pre-clinical research and/or our clinical trials. Clinical trial and pre-clinical expenses include regulatory consultant compensation and fees, research expenses, purchase of plasma, the cost of manufacturing IgG and payments to clinical research organizations and to medical centers for patient recruitment and treatment.

During the nine months ended June 30, 2008 and 2007, research and development expenses included, among others, the cost of IgG used in the clinical trials and research work, payments to medical centers and research labs for clinical trial and pre-clinical trial work, regulatory and scientific consultants compensation, costs related to the maintenance of our registered patents, costs related to the filings of patent applications as well as salaries and related expenses of research and development staff.

During the nine months ended June 30, 2008, research and development expenses totaled $1,350,956, compared to $762,778 for the nine months ended June 30, 2007. The increase is attributable to assay development as well as pre-clinical work related to the filing of the IND for VitiGam™ and collection of plasma from donors.

General and administrative expenses

General and administrative expense includes the salaries and related expenses of our management, consulting costs, legal and professional fees, traveling, business development costs, insurance expenses and other general costs.

For the nine months ended June 30, 2008, general and administrative expenses totaled $1,979,379 compared to $2,902,678 for the nine months ended June 30, 2007. Costs incurred related to general and administrative activities in the nine months ended June 30, 2008 reflect a decrease of $683,000 in salary and related expenses due to lower stock based compensation expense and a reduction of headcount, a decrease of $237,000 in stock based compensation expenses for consultants, a decrease of $43,000 in public and investor relations and a decrease of $35,000 in business development, offset by an increase in professional and legal fees and an increase in general expenses such as office rent and maintenance expenses and communication and IT expenses.

Financial income/expense, net

During the nine months ended June 30, 2008 and 2007, we generated interest income on available cash and cash equivalents balance as well as bank charges.

Liquidity and Capital Resources

Through June 30, 2008, we incurred losses in an aggregate amount of $12,265,847. We have financed our operations from the private placements of equity and debt financings. Through June 30, 2008, we raised a total of $9,538,553, net of transaction costs, through private placements of equity. We anticipate that additional financing will be through similar sources. As of June 30, 2008, we had $861,531 available in cash, most of which is deposited in short term, interest bearing, bank deposits. To implement our business plan, as currently

contemplated, we anticipate we will need approximately $2 million for the remainder of our fiscal year, and approximately $9 million for the twelve months following July 1, 2008.

Although we do not have material financing commitments, management is engaged in ongoing financing discussions with third party investors and existing shareholders to raise the necessary funds for future research and development activities and general and administrative expenses in the public and private equity markets. Although there is no assurance that we will be successful with these initiatives, management expects to secure the necessary financing as a result of the above ongoing discussions.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Planned Expenditures

The estimated expenses referenced herein are in accordance with our business plan. As our technology is still in the development stage, it can be expected that there will be changes in some budgetary items. Our planned expenditures for the twelve months following July 1, 2008 are as follows:

Category	Amount

Research & Development	$	6,318,000
General & Administrative Expenses		2,865,000
Finance Income, net		(75,000	)

Total	$	9,108,000

As previously indicated, we are planning to file an IND with the FDA for VitiGam^TM. Our ability to proceed with this IND application as well as the commencement of the related clinical trial is dependent on several major factors including the ability to attract sufficient financing on terms acceptable to us.

ITEM 3A(T) - CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of June 30, 2008, our management carried out an evaluation, under the supervision of our Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our system of disclosure controls and procedures (as defined by Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, as of the date of their evaluation, for the purposes of recording, processing, summarizing and timely reporting material information required to be disclosed in reports filed by us under the Exchange Act.

Changes in internal controls

There were no changes in our internal controls over financial reporting that occurred during the quarter ended June 30, 2008 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1 - LEGAL PROCEEDINGS

From time to time we may become subject to litigation incidental to our business. We are not currently a party to any legal proceedings.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5 - OTHER INFORMATION

The following disclosure would have otherwise been filed on Form 8-K under the heading “Item 1.01 – Entry into a Material Definitive Agreement” and “Item 3.02 – Unregistered Sales of Equity Securities”.

On August 11, 2008, we executed an Amendment Agreement with ARP Biomed, Ltd. (“ARP”) made as of June, 2008 (the “Amendment Agreement”) amending the Share Purchase Agreement dated November 26, 2007, between the parties and certain other ancillary agreements entered into at the same time. As previously reported in our Form 8-K filed with the Commission on December 19, 2007, the Share Purchase Agreement provided that subject to fulfillment of certain closing conditions, including the receipt of an Israeli tax ruling, ARP will sell to us 12.5% of the issued and outstanding shares of the Subsidiary such that at closing we will own 100% of the issued and outstanding shares of the Subsidiary. In consideration for such sale, we originally agreed to issue to ARP, at closing, 2,697,535 shares of its common stock, a warrant to acquire 1,123,973 shares of its common stock and an additional warrant to acquire 449,589 shares of its common stock. According to the Amendment Agreement, the number of shares of common stock issuable to ARP at closing and upon receipt of an Israeli tax ruling has been increased to 3,389,902 shares of our common stock and no warrants will be issued. Further, the Amendment Agreement amends the Lock-Up Agreement dated as of November 26, 2007 between ARP and the Company by increasing the number of locked-up shares that can be sold during the period after May 26, 2009 from one-sixth per month to one-eight per month. The Amendment Agreement also amends the effective date of the Agreement to Sale of Intellectual Property Agreement dated as of November 26, 2007 between ARP and the Company to the earlier of the receipt of the Israeli tax ruling and June 15, 2008.

Subsequently on August 13, 2008, we conducted a closing of the Share Purchase Agreement as amended by the Amendment Agreement. The 3,389,902 shares of our common stock issued to ARP at closing were offered and sold in reliance upon exemptions from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(2) thereof and/or Rule 506 of Regulation D promulgated thereunder.

Mr. Yair Aloni, a member of our board of directors, is the Chief Executive Officer of ARP and Professor Yehuda Shoenfeld, M.D., our Chief Scientist of the Subsidiary, is an advisor to ARP.

The foregoing description is a summary and is qualified in its entirety by the Amendment Agreement attached as an exhibit hereto and incorporated by reference herein.

ITEM 6 - EXHIBITS

Number		Exhibit

10.1		Amendment Agreement dated as of June, 2008 between ARP Biomed Ltd. and GammaCan International, Inc.
31.1		Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended
31.2		Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as amended
32.1		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)
32.2		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	GAMMACAN INTERNATIONAL, INC. Registrant
Date: August 14, 2008	By:	/s/ Limor Zur-Stoller

		Limor Zur-Stoller Chief Financial Officer